Key Takeaways
- • CPAI trades at $52.47 with $448.09M in assets under management, representing a quantitative equity ETF that has delivered +39.42% returns over the past 12 months as of recent data points.
- • The fund employs an actively managed, model-based approach targeting long-term capital appreciation across US stocks of any market capitalization, with an inception date of November 28, 2023.
- • Portfolio exhibits a beta of 1.22x with a net expense ratio of 0.75%, indicating above-market volatility paired with competitive fee structure; top holdings include AbCellera Biologics (2.85%), Dell Technologies (2.74%), and Super Micro Computer (2.54%).
- • 52-week trading range spans $37.29 to $53.96, with the fund currently trading near its high; dividend yield stands at 0.68% ($0.36 per share) with average daily volume of 68.11K shares.
- • Analyst price targets range from $69.00 to $71.00, suggesting potential upside from current levels for investors with a longer-term horizon.
Summary
Counterpoint Quantitative Equity ETF (CPAI) is an actively managed US equities fund that has emerged as a meaningful player in the broad-market, multi-cap segment since its November 2023 inception. Trading at $52.47 with approximately $448.09M in assets under management, the fund employs a quantitative, model-based stock selection methodology designed to generate long-term capital appreciation while managing downside exposure across companies of varying market capitalizations.
Performance metrics highlight the fund's competitive positioning within its category. Over the trailing 12-month period, CPAI has delivered +39.42% in returns, substantially outpacing the broader equity market backdrop. The fund's beta coefficient of 1.22x indicates that it carries above-market volatility relative to the S&P 500, a characteristic consistent with its active quantitative approach and concentrated positioning in high-conviction ideas. The 52-week trading range of $37.29 to $53.96 reflects this volatility, with current pricing near the upper bound of the range.
The fund's expense structure remains competitive in the actively managed ETF landscape, with a net expense ratio of 0.75%. CPAI generates modest income for shareholders through a 0.68% dividend yield ($0.36 per share), reflecting a focus on capital appreciation over income generation. Average daily trading volume of 68.11K shares provides reasonable liquidity for institutional and retail participants seeking exposure to the strategy.
Portfolio composition reveals concentrated positions in technology and semiconductor-adjacent names: AbCellera Biologics represents the largest single position at 2.85% of assets, followed by Dell Technologies (2.74%) and Super Micro Computer (2.54%). The fund's valuation metrics—price-to-earnings ratio of 10.95 and price-to-book of 2.77—suggest selective positioning relative to the broader market. Analyst consensus targets range from $69.00 to $71.00 per share, implying potential 31–35% upside from current levels for investors maintaining conviction in the quantitative strategy's outperformance thesis.
Performance metrics highlight the fund's competitive positioning within its category. Over the trailing 12-month period, CPAI has delivered +39.42% in returns, substantially outpacing the broader equity market backdrop. The fund's beta coefficient of 1.22x indicates that it carries above-market volatility relative to the S&P 500, a characteristic consistent with its active quantitative approach and concentrated positioning in high-conviction ideas. The 52-week trading range of $37.29 to $53.96 reflects this volatility, with current pricing near the upper bound of the range.
The fund's expense structure remains competitive in the actively managed ETF landscape, with a net expense ratio of 0.75%. CPAI generates modest income for shareholders through a 0.68% dividend yield ($0.36 per share), reflecting a focus on capital appreciation over income generation. Average daily trading volume of 68.11K shares provides reasonable liquidity for institutional and retail participants seeking exposure to the strategy.
Portfolio composition reveals concentrated positions in technology and semiconductor-adjacent names: AbCellera Biologics represents the largest single position at 2.85% of assets, followed by Dell Technologies (2.74%) and Super Micro Computer (2.54%). The fund's valuation metrics—price-to-earnings ratio of 10.95 and price-to-book of 2.77—suggest selective positioning relative to the broader market. Analyst consensus targets range from $69.00 to $71.00 per share, implying potential 31–35% upside from current levels for investors maintaining conviction in the quantitative strategy's outperformance thesis.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.